BlueCrest Capital Management’s Acorda Therapeutics ACOR Stock Holding History

BlueCrest Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-87	Closed	-$10K	–	282
2020 Q1	$10K	Buy	+87	New	+$17.1K	﹤0.01%	211
2018 Q4	–	Sell	-168	Closed	-$397K	–	1527
2018 Q3	$397K	Buy	168 +58	+53%	+$180K	0.01%	884
2018 Q2	$378K	Sell	110 -1	-0.9%	-$3.06K	0.01%	983
2018 Q1	$315K	Buy	+111	New	+$332K	0.01%	1023
2017 Q4	–	Sell	-121	Closed	-$345K	–	1163
2017 Q3	$345K	Buy	+121	New	+$319K	0.01%	599

Other funds holding ACOR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlueCrest Capital Management's ACOR Position: Q2 2020 in Review

BlueCrest Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 87 shares — an estimated $10K sold.

BlueCrest Capital Management first reported a position in ACOR in Q3 2017 and held it in 5 quarters. The position peaked at $397K in Q3 2018. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

BlueCrest Capital Management reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
BlueCrest Capital Management sold 87 Acorda Therapeutics shares in Q2 2020, an estimated $10K.
BlueCrest Capital Management first reported a position in Acorda Therapeutics in Q3 2017 and held it in 5 quarters.
BlueCrest Capital Management's Acorda Therapeutics position peaked at $397K in Q3 2018.
79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on BlueCrest Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.